Prophylactic vaccines are preventive vaccines designed to protect individuals from specific infectious diseases before they encounter the causative pathogens. Unlike therapeutic vaccines, which are administered after infection to treat or manage diseases, prophylactic vaccines aim to establish immunity before exposure. Prophylactic vaccines work by stimulating the immune system to produce an immune response, including the production of antibodies and memory cells. This immune memory allows the body to mount a rapid and effective defense upon encountering the actual pathogen, preventing or mitigating disease. Common examples of prophylactic vaccines include those against measles, mumps, rubella (MMR), polio, hepatitis B, and various bacterial and viral infections. Vaccination schedules typically include multiple doses to ensure robust and lasting immunity. The widespread use of prophylactic vaccines has significantly reduced the incidence of many infectious diseases, contributing to public health improvements globally. Ongoing research focuses on developing new prophylactic vaccines, optimizing existing ones, and addressing challenges like vaccine hesitancy to enhance global disease prevention efforts.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe